Heart Test Laboratories, Inc. (d/b/a HeartSciences) is medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to expand and improve an ECG’s clinical usefulness. The Company’s objective is to make an ECG a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. HeartSciences’ first product candidate for FDA clearance, the MyoVista wavECG, or the MyoVista, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction which has traditionally only been available through the use of cardiac imaging. The MyoVista also provides conventional ECG information in the same test. The business model, which involves the use of the MyoVista device and consumables for each test, is expected to be “razor-razorblade” as the electrodes used with the MyoVista are proprietary to HeartSciences, and new electrodes are required for every test performed. Additional information about the Company is available at www.heartsciences.com.
Company profile
Ticker
HSCS
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Zimmer Biomet • Enovis • Steris • Intuitive Surgical • Edwards Lifesciences • Avanos Medical • MSA Safety • INVACARE • Align Technology • Surgalign ...
SEC CIK
Corporate docs
Subsidiaries
a Texas corporation ...
IRS number
261344466
HSCS stock data
Latest filings (excl ownership)
424B3
Prospectus supplement
18 Mar 24
8-K
HeartSciences Reports Third Quarter Fiscal 2024 Financial Results
14 Mar 24
10-Q
2024 Q3
Quarterly report
14 Mar 24
EFFECT
Notice of effectiveness
14 Mar 24
S-1
IPO registration
5 Mar 24
S-8
Registration of securities for employees
26 Feb 24
8-K
Submission of Matters to a Vote of Security Holders
15 Feb 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
31 Jan 24
8-K
Other Events
25 Jan 24
DEFA14A
Additional proxy soliciting materials
18 Jan 24
Latest ownership filings
SC 13G
Matthews Holdings Southwest, Inc.
11 Dec 23
SC 13G
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
27 Nov 23
SC 13D
Simpson Andrew
14 Jun 23
SC 13D
HILZ MARK T
14 Jun 23
4
Andrew Simpson
22 Mar 23
4
Brian Szymczak
22 Mar 23
4
David R. Wells
22 Mar 23
4
Bruce Bent
22 Mar 23
4
MARK T HILZ
22 Mar 23
4
Danielle Watson
22 Mar 23
Financial summary
Quarter (USD) | Oct 23 | Jul 23 | Apr 23 | Jan 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Apr 23 | Apr 22 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 100.14 k | 100.14 k | 100.14 k | 100.14 k | 100.14 k | 100.14 k |
Cash burn (monthly) | 158.50 k | 247.99 k | 523.31 k | 484.05 k | 329.40 k | 439.52 k |
Cash used (since last report) | 934.06 k | 1.46 mm | 3.08 mm | 2.85 mm | 1.94 mm | 2.59 mm |
Cash remaining | -833.92 k | -1.36 mm | -2.98 mm | -2.75 mm | -1.84 mm | -2.49 mm |
Runway (months of cash) | -5.3 | -5.5 | -5.7 | -5.7 | -5.6 | -5.7 |
Institutional ownership, Q3 2023
0.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 3 |
Opened positions | 0 |
Closed positions | 12 |
Increased positions | 2 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 17.72 mm |
Total shares | 620.82 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Armistice Capital | 352.94 k | $17.65 mm |
Clear Street | 266.46 k | $13.00 k |
UBS UBS Group AG - Registered Shares | 1.41 k | $63.00 k |
Proequities | 0.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
20 Mar 23 | Bruce Bent | Director Stock Option Common Stock | Grant | Acquire A | No | No | 0.97 | 50,000 | 48.50 k | 50,000 |
20 Mar 23 | Mark T Hilz | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 0.97 | 300,000 | 291.00 k | 300,000 |
20 Mar 23 | Danielle Watson | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 0.97 | 75,000 | 72.75 k | 75,000 |
20 Mar 23 | Andrew Simpson | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 0.97 | 300,000 | 291.00 k | 300,000 |
20 Mar 23 | Brian Szymczak | Director Stock Option Common Stock | Grant | Acquire A | No | No | 0.97 | 50,000 | 48.50 k | 50,000 |
News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
25 Apr 24
Recap: Heart Test Laboratories Q3 Earnings
14 Mar 24
HeartSciences' Announces Peer-Reviewed Publication Evaluating Use Of MyoVista Technology To Detect Asymptomatic Left Ventricular Dysfunction In Patients With Type 2 Diabetes
12 Mar 24
Why United Natural Foods Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
6 Mar 24
12 Health Care Stocks Moving In Wednesday's Intraday Session
6 Mar 24